Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
72°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Acorda Therapeutics
Acorda Therapeutics Announces Delisting from Nasdaq
April 15, 2024
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
ACORQ
OTC
Acorda Therapeutics Announces Nasdaq Delisting Notification
April 03, 2024
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
April 01, 2024
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
March 25, 2024
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
January 11, 2024
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
November 06, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
November 06, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
August 02, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
August 01, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Tom Burns Elected to the Acorda Therapeutics Board of Directors
June 28, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 26, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
June 02, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
May 31, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
May 30, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
May 10, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
May 08, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
May 04, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
April 24, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
April 03, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
March 27, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
ESTEVE Launches INBRIJA® in Spain
March 07, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
March 06, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
February 14, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics to Present at Sequire Biotechnology Conference
January 31, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
January 05, 2023
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
December 22, 2022
From
Acorda Therapeutics
Via
Business Wire
Tickers
ACOR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.